MMPredict consortium presents data on quality of life and cost effectiveness of risk at EHA 2019

MMPredict is a HORIZON 2020 project, which Myeloma Patients Europe (MPE) is involved in, aimed at clinically validating a personalised medicines tool that predicts the most effective treatment options for myeloma patients. As part of MMPredict, MPE has been involved in the development and dissemination of a survey  assessing the quality of life of European myeloma patients, particularly relating to currently available myeloma treatments and how side-effects impact upon them.